| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Department of Surgery*
and the Dental
and Craniofacial Research Institute,
University of California, Los Angeles, California; Mount Sinai
Hospital,
New York, New York; the Shriners
Hospital for Crippled Children,§
Tampa,
Florida; and the Institute of Reconstructive Plastic
Surgery,¶
New York, New York
Transforming growth factor-ß (TGF-ß1, -ß2, and -ß3) has been implicated in the ontogenetic transition from scarless fetal repair to adult repair with scar. Generally, TGF-ß exerts its effects through type I and II receptors; however, TGF-ß modulators such as latent TGF-ß binding protein-1 (LTBP-1), decorin, biglycan, and fibromodulin can bind and potentially inhibit TGF-ß activity. To more fully explore the role of TGF-ß ligands, receptors, and potential modulators during skin development and wound healing, we have used a rat model that transitions from scarless fetal-type repair to adult-type repair with scar between days 16 and 18 of gestation. We showed that TGF-ß ligand and receptor mRNA levels did not increase during the transition to adult-type repair in fetal skin, whereas LTBP-1 and fibromodulin expression decreased. In addition, TGF-ß1 and -ß3; type I, II, and III receptors; as well as LTBP-1, decorin, and biglycan were up-regulated during adult wound healing. In marked contrast, fibromodulin expression was initially down-regulated in adult repair. Immunostaining demonstrated significant fibromodulin induction 36 hours after injury in gestation day 16, but not day 19, fetal wounds. This inverse relationship between fibromodulin expression and scarring in both fetal and adult rat wound repair suggests that fibromodulin may be a biologically relevant modulator of TGF-ß activity during scar formation.
This article has been cited by other articles:
 |
|
 |
|
  M. S. Agren and M. Werthen The Extracellular Matrix in Wound Healing: A Closer Look at Therapeutics for Chronic Wounds International Journal of Lower Extremity Wounds, June 1, 2007; 6(2): 82 - 97. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Wen, Y.Y. Zhao, S. Li, M.L. Polan, and B.H. Chen Differences in mRNA and protein expression of small proteoglycans in vaginal wall tissue from women with and without stress urinary incontinence Hum. Reprod., June 1, 2007; 22(6): 1718 - 1724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Goldberg, D. Septier, A. Oldberg, M. F. Young, and L. G. Ameye Fibromodulin-deficient Mice Display Impaired Collagen Fibrillogenesis in Predentin as Well as Altered Dentin Mineralization and Enamel Formation J. Histochem. Cytochem., May 1, 2006; 54(5): 525 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Levens, X. Luo, L. Ding, R. S. Williams, and N. Chegini Fibromodulin is expressed in leiomyoma and myometrium and regulated by gonadotropin-releasing hormone analogue therapy and TGF-{beta} through Smad and MAPK-mediated signalling Mol. Hum. Reprod., July 1, 2005; 11(7): 489 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Mayr, D. Bund, M. Schlee, A. Moosmann, D. M. Kofler, M. Hallek, and C.-M. Wendtner Fibromodulin as a novel tumor-associated antigen (TAA) in chronic lymphocytic leukemia (CLL), which allows expansion of specific CD8+ autologous T lymphocytes Blood, February 15, 2005; 105(4): 1566 - 1573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Soo, S. R. Beanes, F.-Y. Hu, X. Zhang, C. Dang, G. Chang, Y. Wang, I. Nishimura, E. Freymiller, M. T. Longaker, et al. Ontogenetic Transition in Fetal Wound Transforming Growth Factor-{beta} Regulation Correlates with Collagen Organization Am. J. Pathol., December 1, 2003; 163(6): 2459 - 2476. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. WERNER and R. GROSE Regulation of Wound Healing by Growth Factors and Cytokines Physiol Rev, July 1, 2003; 83(3): 835 - 870. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Huang, Y. Kim, M. L. A. Caramori, A. J. Fish, S. S. Rich, M. E. Miller, G. B. Russell, and M. Mauer Cellular Basis of Diabetic Nephropathy: II. The Transforming Growth Factor-{beta} System and Diabetic Nephropathy Lesions in Type 1 Diabetes Diabetes, December 1, 2002; 51(12): 3577 - 3581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Klein, Y. Tu, G. A. Stolovitzky, M. Mattioli, G. Cattoretti, H. Husson, A. Freedman, G. Inghirami, L. Cro, L. Baldini, et al. Gene Expression Profiling of B Cell Chronic Lymphocytic Leukemia Reveals a Homogeneous Phenotype Related to Memory B Cells J. Exp. Med., December 3, 2001; 194(11): 1625 - 1638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yamate, M. Maeda, S. J. Benn, J. E. Laithwaite, A. Allan, M. Ide, M. Kuwamura, T. Kotani, S. Sakuma, and J. Lamarre Differential Effects of Transforming Growth Factor-{beta}1, a Fibrogenic Factor, on Macrophage-Like Cells (HS-P) and Myofibroblastic Cells (MT-9) In Vitro Toxicol Pathol, June 1, 2001; 29(4): 483 - 491. [Abstract] [PDF]
|
|
|
|
|
|
E. Levens, X. Luo, L. Ding, R. S. Williams, and N. Chegini Fibromodulin is expressed in leiomyoma and myometrium and regulated by gonadotropin-releasing hormone analogue therapy and TGF-{beta} through Smad and MAPK-mediated signalling Mol. Hum. Reprod., July 1, 2005; 11(7): 489 - 494. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
